Año 2020 / Volumen 112 / Número 10
Editorial
Autoimmune hepatitis, primary sclerosing cholangitis, and inflammatory bowel disease. Sequential overlap syndrome: a twist to the mosaic of autoimmunity

745-747

DOI: 10.17235/reed.2020.7512/2020

Pilar López Serrano, Juan Turnes Vázquez,

Resumen
Autoimmune liver diseases can overlap resulting in a new entity, phenotypically different from those pathologies that converge, and that demonstrates the complexity of our immune system. Sequential overlap syndrome is the consecutive presentation, separated by a variable period of time, of two liver autoimmune diseases, mostly autoimmune hepatitis and primary biliary cholangitis. This syndrome constitutes a challenge both in its diagnosis and in its treatment given the exceptional nature of its presentation. The theory of a mosaic of autoimmunity is proposed to describe this phenomenon.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Czaja AJ. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol. 2013; 27: 417–423. doi: 10.1155/2013/198070.
2. Abdalian R, Dhar P, Jhaveri K et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology. 2008;47:949. doi:10.1002/hep.22073.
3. Tsaitas C, Semertzidou A, Sinakos E. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol. 2014;6:178-187. doi:10.4254/wjh.v6.i4.178.
4. Abdo AA, Bain VG, Kichian K et al. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology 2002; 36:1393. https://doi.org/10.1053/jhep.2002.37200.
5. Efe C, Ozaslan E, Heurgué-Berlot A, et al. Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2014;26:532-537. doi:10.1097/MEG.0000000000000075.
6. Keskin O, Idilman R. Sequential development of acute autoimmune hepatitis may lead to a serious clinical picture in primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2015;27(10):1228-1229. doi:10.1097/MEG.0000000000000417.
7. Pinto C, Lagos I, Brahm J. Sequential overlap syndrome: Clinical Characteristics of 10 patients. XXV Annual Meeting of The Latin American Association for the Study of the Liver . República Dominicana. September 2018. Annal of hepatol.2018; 17:1123-1124.
8. Domschke W, Klein R, Terracciano LM, et al. Sequential occurrence of primary sclerosing cholangitis and autoimmune hepatitis type III in a patient with ulcerative colitis: a follow up study over 14 years. Liver. 2000;20(4):340-345. doi:10.1034/j.1600-0676.2000.020004340.x.
9. Nuñez P, Sedano R, Quera R et al. Síndrome de Superposición Autoinmune Secuencial (Hepatitis Autoinmune/ Colangitis Esclerosante Primaria) y Enfermedad Inflamatoria Intestinal: A propósito de 3 casos clínicos. Rev Esp Enferm Dig 2020;112(9):xxx-xxx.
10. Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54(2):374-385. doi:10.1016/j.jhep.2010.09.002.
11. Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54(2):374-385. doi:10.1016/j.jhep.2010.09.002
12. Sarfaraz S, Anis S. Multiple Autoimmune Syndrome: An Unusual Combination of Autoimmune Disorders (in press). Rev Recent Clin Trials. doi:10.2174/1574887115666200621184110.
13. de Vries AB, Janse M, Blokzijl H et al. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015;21(6):1956-1971. doi:10.3748/wjg.v21.i6.1956.
14. Palmela C, Peerani F, Castaneda D et al. Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features. Gut Liver. 2018;12(1):17-29. doi:10.5009/gnl16510.
15. Núñez F P, Quera P R, Gomollón F. Primary sclerosing cholangitis and inflammatory bowel disease: Intestine-liver interrelation. Colangitis esclerosante primaria y enfermedad inflamatoria intestinal: interrelación intestino-hígado. Gastroenterol Hepatol. 2019;42:316-325. doi:10.1016/j.gastrohep.2019.02.004.
16. de Krijger M, Wildenberg ME, de Jonge WJ et al. Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. J Hepatol. 2019;71:603-615. doi:10.1016/j.jhep.2019.05.006.
17. Danese S, Semeraro S, Papa A et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11(46):7227-7236. doi:10.3748/wjg.v11.i46.7227.
18. Lazaridis KN, LaRusso NF. Primary Sclerosing Cholangitis. N Engl J Med. 2016;375:1161-1170. doi:10.1056/NEJMra1506330.
19. Trivedi PJ, Chapman RW. PSC, AIH and overlap syndrome in inflammatory bowel disease. Clin Res Hepatol Gastroenterol. 2012;36:420-436. doi:10.1016/j.clinre.2011.10.007.
20. Lunder AK, Hov JR, Borthne A et al. Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease. Gastroenterology. 2016;151:660-669.e4. doi:10.1053/j.gastro.2016.06.021.
21. Belle A, Laurent V, Pouillon L et al. Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease. Dig Liver Dis. 2018;50:1012-1018. doi:10.1016/j.dld.2018.06.024.
22. Eksteen B, Heatherington J, Oshiomogo J et al. Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease. J Hepatol 64 (2016) S199. DOI:https://doi.org/10.1016/S0016-5085(16)34283-4.
23. Caron B, Peyrin-Biroulet L, Pariente B et al. Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study. J Crohns Colitis. 2019;13(10):1239-1247. doi:10.1093/ecco-jcc/jjz088.
24. Lynch KD, Chapman RW, Keshav S et al. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020;18(1):179-187.e6. doi:10.1016/j.cgh.2019.05.013.
25. Christensen B, Micic D, Gibson PR et al. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018;47(6):753-762. doi:10.1111/apt.14525
Artículos relacionados

Carta

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Carta

Linfoma T hepatoesplénico y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2023.9472/2023

Carta

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Carta

Hepatitis autoinmune desencadenada por la COVID-19

DOI: 10.17235/reed.2021.8045/2021

Revisión

Enfermedad inflamatoria intestinal y trasplante de órganos sólido

DOI: 10.17235/reed.2020.7361/2020

Carta

Hepatitis aguda por olmesartán: una entidad infrecuente

DOI: 10.17235/reed.2020.7236/2020

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Caso Clínico

Lesiones serradas en pacientes con enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2019.5910/2018

Editorial

Redes sociales online y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2018.5496/2018

Carta al Editor

Hipertensión portal idiopática por tiopurinas

DOI: 10.17235/reed.2018.5256/2017

Caso Clínico

The clinical extremes of autoimmune cholangitis

DOI: 10.17235/reed.2017.4167/2015

Instrucciones para citar
López Serrano P, Turnes Vázquez J. Autoimmune hepatitis, primary sclerosing cholangitis, and inflammatory bowel disease. Sequential overlap syndrome: a twist to the mosaic of autoimmunity. 7512/2020


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1047 veces.
Este artículo ha sido descargado 310 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 08/09/2020

Aceptado: 10/09/2020

Prepublicado: 21/09/2020

Publicado: 07/10/2020

Tiempo de prepublicación: 13 días

Tiempo de edición del artículo: 29 días


Compartir
Este artículo ha sido valorado por 2 lectores .
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas